A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
A phase 1/2 trial of Armored and GPC3-targeted autologous CAR T-cell in hepatocellular carcinoma, run by Shanghai AbelZeta Ltd., now recruiting.
Overview
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06590246 by Shanghai AbelZeta Ltd., with 121 participants planned, started 2024-09-30 and due to reach its primary completion in 2030-04-30. Interventions recorded: Armored and GPC3-targeted autologous CAR T-cell.
Similar pages
not linked directly; found by shared links- TrialA Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Shares Shanghai AbelZeta and the tag pipeline.
- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialTo Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Hepatocellular carcinoma and the tag pipeline.